⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

September 3, 2024

Figure S8 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways

Signe K. Skadborg Simone Maarup Arianna Draghi Annie Borch Sille Hendriksen Filip Mundt Vilde Pedersen Matthias Mann Ib Jarle Christensen Jane Skjøth-Ramussen Christina W. Yde Bjarne Winther Kristensen Hans Skovgaard Poulsen Benedikte Hasselbalch Inge Marie Svane Ulrik Lassen Sine Reker Hadrup

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 8 Transcriptomic comparison of NIVO versus control patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Skadborg et al. (2024) studied this question.

synapsesocial.com/papers/68e598e8b6db64358753398e https://doi.org/10.1158/2326-6066.26926006

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S15 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
2Figure S9 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
3Figure S3 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
4Figure S10 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024
5Figure S6 from Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways2024